US FDA approves Octapharma's Wilate for von Willebrand disease
This article was originally published in Scrip
The US FDA has approved Octapharma's Wilate for the treatment of spontaneous and trauma-induced bleeding episodes in patients with severe von Willebrand disease (VWD), as well as in patients with mild or moderate VWD in whom the use of desmopressin – a standard of care that acts by promoting the release of von Willebrand factor – is known or suspected to be ineffective or contraindicated. The product will be launched next year.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.